Results 31 to 40 of about 10,060 (149)

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China

Pediatric Rheumatology Online Journal
Objective Cryopyrin-associated periodic syndrome (CAPS) is characterized by excessive IL-1β release resulting in systemic and organ inflammation. As an anti-IL-1 agent, canakinumab has been approved with all CAPS phenotypes in USA and European countries.
Xiaona Zhu, Jiaqi Fan, Yanyan Huang, Yongbin Xu, Zhi Yang, Ruohang Weng, Ying Luo, Jun Yang, Tingyan He   +8 more
doaj   +1 more source

Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

International Journal of Immunopathology and Pharmacology, 2021
Introduction The fully-human monoclonal anti-interleukin (IL)-1β antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to ...
Antonio Mastroianni, Sonia Greco, Luciana Chidichimo, Filippo Urso, Francesca Greco, Maria V Mauro, Valeria Vangeli   +6 more
doaj   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

TRIM31–LOX‐1 Axis: A Novel Therapeutic Frontier in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis, driven by a vicious cycle of lipid accumulation and chronic inflammation, underlies most cardiovascular diseases. Macrophages exacerbate this process by internalizing oxidized low‐density lipoprotein (oxLDL), forming foam cells, and releasing inflammatory mediators. A recent study published in Circulation identified the TRIM31–
Qian Zhang, Cheng Xue Qin
wiley   +1 more source

Experience with canakinumab in a patient with gout and IgA nephropathy

Современная ревматология, 2019
The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine ...
E. V. Ilyinykh, M. S. Eliseev
doaj   +1 more source

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

RMD Open, 2021
Objective To report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS ...
Ulrich A Walker, Jasmin B Kuemmerle-Deschner, Jeremy Levy, Eleni Vritzali, Hal M Hoffman, Tom van der Poll, PHILIP N HAWKINS, Hugh H Tilson, Stephanie Noviello   +8 more
doaj   +1 more source

Senotherapeutics for Knee Osteoarthritis

Medicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman, Girish Pattappa, Patrick Pann, Stephan Reppenhagen, Maximilian Rudert, Peter Angele, Denitsa Docheva   +6 more
wiley   +1 more source

Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry

Pediatric Rheumatology Online Journal
Background Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation.
Colleen Correll, Alis Burciu, Amita Bansal, Anne Dennos, Deepak Narayanswamy, Elodie Aubrun, Laura E. Schanberg, Li Yuhan, Rahel Schneider, Stephen Balevic, Yukiko Kimura, Timothy Beukelman, for the CARRA Registry investigators   +12 more
doaj   +1 more source